Biocelect Pty News Today

Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe ac...

Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe ac...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

(RTTNews) - Novavax Inc. (NVAX) said Wednesday that New Zealands Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) CO...

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md.,...

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

(RTTNews) - Novavax, Inc. (NVAX) announced that Nuvaxovid COVID-19 vaccine received expanded manufacturing and marketing approval in Japan to prev...

In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine historyGAITHER...

Maryland-based Novavax Inc. recently announced the first doses of its protein-based COVID-19 vaccine would be available to New Zealanders beginning this week. As of March 14, 2022, the two-dose Nuvaxovid™ COVID-19 Vaccine (adjuvanted) for active immunization to prevent COVID-19 in individuals 18 years of age and older will be available throughout New Zealand.

The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care.